Innovations and Outcomes (CIOR) Presentations and Research

This quarterly report is a summary of the monthly Faculty Research Newsletter. Journal links may require subscriptions or a log-in through the Columbia library while PubMed links are accessible to all.

Presentations

September 2017

International Society on Thrombosis and Hemostasis (ISTH) Congress 2017
Berlin, Germany, July 8-13, 2017

  • Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism.

International Society for Pharmacoepidemiology (ISPE) 33rdInternational Conference on Pharmacoepidemiology
Montreal, Quebec, Canada, August 26-30, 2017

  • Ogbomo A, Keshishian A, Xie L, Lin Y, Baser O. A Descriptive analysis of the health care utilization and costs of patients diagnosed with multiple myeloma in the US Medicare population.
  • Pandya S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with heart failure in the US Veterans Health Administration population.
  • Vaidya N, Xie L, Wang Y, Du J, Baser O. Evaluating the economic burden and health care utilization of migraine in the US Department of Defense population. International Society for Pharmacoepidemiology
  • Zhang Q, Xie L, Keshishian A, Lin Y, Baser O. Examining the health care utilization and costs among elderly patients with chronic obstructive pulmonary disease in the United States.

European Society of Cardiology (ESC) Congress 2017
Barcelona, Spain, August 26-30, 2017

  • Peacock WF, Coleman C, Wells P, Fermann GJ, Wang L, Baser O, Schein J, Crivera C. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care.
  • Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger J. Short and intermediate term all-cause mortality among newly-diagnosed heart failure patients in the US Medicare population.

June 2017

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting
Boston MA, May 20-24, 2017

  • Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population.
  • Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with pneumonia in the US Veterans Health Administration population.
  • Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with clostridium difficile infection in the US Veterans Health Administration population.
  • Lin Y, Ogbomo A, Wang Y, Xie L, Yuce H, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with myelodysplastic syndrome in the US Medicare population.
  • Ogbomo A, Lin Y, Wang Y, Xie L, Yuce H, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with lymphoma in the US Medicare population.
  • Vaidya N, Tan H, Xie L, Wang Y, Baser O. Evaluating the economic burden and health care utilization of rheumatoid arthritis patients in the US Department of Defense population.
  • Xie L, Vaidya N, Wang Y, Tan H, Baser O. Evaluating the economic burden and health care utilization of prostate cancer patients in the US Department of Defense population.
  • Du J, Xie L, Keshishian A, Zhang Q, Yuce H, Baser O. Assessing the hospital readmission and mortality rates among elderly patients with chronic obstructive pulmonary disease.
  • Xie L, Zhang Q, Baser O, McGuire M. Examining the health care resource use and economic costs associated with acute myeloid leukemia among Medicare patients.

American Thoracic Society (ATS) International Conference 2017
Washington, DC, May 19-24, 2017

  • Ganapathy V, Xie L, Keshishian A, Zhang Q, Baser O. Continuing care with nebulized bronchodilators after hospital discharge and impact on readmissions: Analysis of Medicare COPD beneficiaries receiving arformoterol vs nebulized short-acting agents.

April 2017

13th International Conference on Alzheimer's & Parkinson's
Vienna, Austria, March 29-April 2, 2017

  • Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Rates of Institutionalization among Newly Diagnosed AD Patients.

Academy of Managed Care Pharmacy Managed Care Specialty Pharmacy Annual Meeting
Denver, CO, March 27-30, 2017

  • Lee S, Xie L, Wang Y, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
  • Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Prescription fill patterns after reaching the Medicare Part D coverage gap among chronic obstructive pulmonary disease patients on maintenance bronchodilators.
  • Ye F, Zhou FL, Xie L, Kariburyo F, Meneghini L. Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin glargine 300 U/mL (Gla-300) from insulin glargine 100 U/mL (Gla-100) in real-world US treatment settings.
  • Chipps B, Ferro T, Wang L, Shrestha S, Baser O, Parikh R. Healthcare costs in asthma and/or chronic obstructive pulmonary disease patients using albuterol inhalation aerosol with and without an integrated dose counter.

National Comprehensive Cancer Network (NCCN) 22nd Annual Conference
Orlando, FL, March 23-25, 2017

  • Pandya S, Abouzaid S, Xie L, Parikh K, Baser O, Patel MI. Real-world health care costs among newly-diagnosed multiple myeloma patients in the United States veteran population (FY 2011-2015).

American College of Cardiology (ACC) 66th Annual Scientific Session & Expo
Washington, DC, March 17-19, 2017

  • Amin A, Keshishian A, Trocio J, Dina O, Le H, Zhang Q, Baser O, Vo L. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population.

AMDA (Society for Post-acute and Long-term Care Medicine) Annual Conference 2017
Phoenix, AZ, March 16-19, 2017

  • Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Hospital readmissions among chronic obstructive pulmonary disease patients treated in skilled nursing facilities in the US.

American Academy of Dermatology (AAD) 2017 Annual Meeting
Orlando, FL, March 3-7, 2017

  • Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population.

December 2016

ASH Hematology 58th Annual Meeting & Exposition, San Diego, CA
December 3-6, 2016

  • Parikh K, Pandya S, Abouzaid S, Baser O, Xie L, Patel MI. Real world treatment outcomes and cost among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide.
  • Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population.

See also AHA Wang L, et al.

November 2016

Academy of Managed Care Pharmacy (AMCP) Nexus. National Harbor, MD
October 3-6, 2016

  • Xie L, Zhou S, Kariburyo F, Baser O, Fan T. Clinical and economic outcomes in patients with type 2 diabetes switching from basal insulin plus rapid-acting insulin to basal insulin plus glucagon-like peptide-1: A real-world observational study.

International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress 2016. Vienna, Austria
October 29 - November 2, 2016

  • Wang L, Li L, Pandya S, Baser O. Evaluating socio-demographic characteristics of patients in the United states Department of Defense population.
  • Wang L, Li L, Pandya S, Baser O. A real-world evaluation of the clinical and economic burden of United States veteran patients with post-traumatic stress disorder. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European.
  • Wang L, Li L, Zhou X, Pandya S, Baser O. Evaluation of the clinical characteristics and economic burden of United States veteran patients diagnosed with the Hepatitis C virus.
  • Wang L, Li L, Zhou X, Pandya S, Baser O. Assessing the clinical and economic burden of prostate cancer in the United States veteran population.
  • Cinaroglu S, Baser O. Spatial distribution of the total number of medical devices in Turkey: a classification analysis.
  • Cinaroglu S, Baser O. Socio-economic status and self-rated health: are they good predictors of income? An analysis of survey panel data from Turkey.
  • Cinaroglu S, Baser O. Understanding the relationship between effectiveness and outcome indicators in health care.
  • Cinaroglu S, Guzel E, Baser O. The relationship between medical innovation and health expenditures.
  • Xie L, Zhang Q, Xin K, Wang Y, Yuce H, Özenbas D, Baser O. Health care utilization and economic burden of pancreatic cancer in the US Medicare population.
  • Xie L, Vaidya N, Xin K, Keshishian A, Yuce H, Özenbas D, Baser O. Evaluating the economic burden and health care utilization of lung cancer in the US Medicare population.
  • Xie L, Vaidya N, Xin K, Kariburyo MF, Yuce H, Baser O. evaluating the economic burden and health care utilization of breast cancer in the US Medicare population.

American Heart Association (AHA) Scientific Sessions 2016. New Orleans, LA
November 12-16, 2016

  • Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Effectiveness of rivaroxaban among patients diagnosed with pulmonary embolism.
  • Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism: Focus on net clinical impact.

Publications

September 2017

  • Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population. Curr Med Res Opin. 2017 Jun 21:1-32.
    Journal link | PubMed link
  • Bent-Ennakhil N, Coste F, Xie L, Sanon Aigbogun M, Wang Y, Kariburyo F, Hartry A, Baser O, Neumann P, Fillit H. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients. Neurol Ther. 2017;6(1):131-144.
    Journal link | PubMed link
  • Brekke L, Buysman E, Grabner M, Ke X, Xie L, Baser O, Wei W. The use of decomposition methods in real-world treatment benefits evaluation for patients with type 2 diabetes initiating different injectable therapies: Findings from the INITIATOR study. Value Health. 2017 Jul 11.
    Journal link
  • Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining impact of medication adherence on risk of subsequent fracture among women with a fragility fracture in the US Medicare population. J Manag Care Pharm. Published online August 22, 2017.
    Journal link
  • Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int. 2017 May 23.
    Journal link | PubMed link
  • Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Overall effectiveness of rivaroxaban in patients with pulmonary embolism. Clin Ther. 2017 Jun 23.
    Journal link | PubMed link

June 2017

  • Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. Osteoporos Int. 2017 May 23. doi: 10.1007/s00198-017-4072-6. [Epub ahead of print]
    Journal link | PubMed link
  • Bent-Ennakhil N, Coste F, Xie L, Aigbogun MS, Wang Y, Kariburyo F, Hartry A, Baser O, Neumann P, Fillit H. A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients. Neurol Ther. 2017 May 15. doi: 10.1007/s40120-017-0067-7. [Epub ahead of print]
    Journal link | PubMed link

December 2016

  • Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. J Med Econ. 2016 Dec;19(12):1175-1186.
    Journal link | Pubmed link
  • Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju CV, Schein JR. Patterns of international normalized ratio values among new warfarin patients with nonvalvular atrial fibrillation. Blood Coagul Fibrinolysis. 2016 Dec;27(8):899-906.
    Journal link | Pubmed link
  • Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and Costs in Clostridium difficile Infection Among the Elderly in the United States. Infect Control Hosp Epidemiol. 2016 Nov;37(11):1331-1336.
    Journal link | Pubmed link
  • Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. BMC Geriatr. 2016 Nov 25;16(1):193.
    Journal link | Pubmed link